

# XXVII Jornadas SOLACI -- 9º Región Andina



**8 / 9 de Octubre 2015**  
**LIMA - PERU**



## **Miniconferencia:** **Estado actual de la Intervención en bifurcaciones**



Costantino R. Costantini, M.D., Ph.D., F.A.C.C.  
Hospital Cardiológico Costantini  
Fundação Francisco Costantini  
Curitiba - Brasil

Jueves 8 de Octubre 2015; 14h45-15h00

# XXVII Jornadas SOLACI -- 9º Región Andina



**8 / 9 de Octubre 2015**  
**LIMA - PERU**



**Conflicto de Interese: Costantino R Costantini**

**MEDICO – CARGIOLOGO - INTERVENCIONISTA**

# Coronary Bifurcation

## Clinical Doubts

MORTAL RISK OF INTERVENTION IS MORE

**CLOSELY ASSOCIATED WITH**

**COMPLEX PATIENTS**

THAN WITH

**COMPLEX LESIONS**

**CLINICAL RESPONSIBILITY !!!**

Complications of Interventional Cardiology - "Beyond Your Wildest Imagination"

*Barry D. Rutherford, MD*

## Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings

Coronary bifurcations account for 15-20% of all percutaneous coronary interventions (PCI) and remain one of the most challenging lesions in interventional cardiology in terms of procedural success rate as well as long-term cardiac events. The optimal management of bifurcation lesions is still, despite a fast growing scientific literature in the field, the subject of considerable debate, where one of the concerns is the potential increased risk of late stent thrombosis associated with treatment complexity<sup>1</sup>.

EuroIntervention. 2006;2:149-53  
EuroIntervention 2014;10:545-60



# BIFURCAÇÃO IVUS

**CÁLCIO**

**ROTA**

**SEM CÁLCIO**

**BALÃO/BALÃO  
STENT/BALÃO  
STENT/STENT**

**VASOS <2.5mm**  
**KISSING BALLOON**  
**KISSING GUIA**

**VASOS >2.5 <3.0mm**  
**KISSING BALLOON**  
**STENT ?**

**VASO > 3.0mm**  
**KISSING BALLOON**

**RAMO LATERAL**  
**S/ LESÃO RESIDUAL**  
**STENT/ BALÃO**


**RAMO LATERAL**  
**>2.5mm COM/ LESÃO**  
**RESIDUAL OU DISSECÇÃO**  
**STENT/ STENT**

**ANGULO <90°**  
**CULOTTES**

**ANGULO RETO**  
**"T"**

# In-Hospital Mortality of Coronary Bifurcation ST

173 cases of stent thrombosis from 5 US centers between  
2005 and 2010




Armstrong EJ, et al. JACC Cardiovasc Interv. 2012;5:57-63



# SIDE BRANCH

COMO ATUAR



I) Importancia Anatomica

II) Localizacao e Extensao da Lesao

Lesao Ostial > 10 mm de extensao > 2.5mm de diametro

# Abordagem das Bifurcações 1 vs. 2 stents


# BIFURCAÇÃO



1. Colombo. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS Study. *Circulation* 2009;119(1):71-8.
2. Brar. Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials. *EuroIntervention*. 2009 Sep;5(4):475-84.
3. Zamani. Long-term risk of clinical events from stenting side-branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: An observational meta-analysis. *Catheter Cardiovasc Interv*. 2010 Sep 7.
4. Athappan. True coronary bifurcation lesions: meta-analysis and review of literature. *J Cardiovasc Med (Hagerstown)*. 2010 Feb;11(2):103-10.
5. Hildick-Smith. Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies. *Circulation* 2010;121:1235-43.
6. Niccoli. Coronary bifurcation lesions: to stent one branch or both? A meta-analysis of patients treated with drug eluting stents. *Int J Cardiol*. 2010 Feb 18;139(1):80-91.
7. Cheng. Randomized study on T stenting and small protrusion technique versus simple stenting for patients with coronary artery bifurcation lesions and with big size side branch. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2010 Feb;38(2):131-4.
8. Chen. A Randomized Clinical Study Comparing Double Kissing Crush With Provisional Stenting for Treatment of Coronary Bifurcation Lesions Results From the DKCRUSH-II Trial. *J Am Coll Cardiol*. 2011 Feb 22;57(8):914-20
9. Behan. Simple or Complex Stenting for Bifurcation Coronary Lesions: A Patient-Level Pooled-Analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. *Circ Cardiovasc Interv*. 2011 Jan 4.
10. Niemelä M. Randomized Comparison of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation in Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting The Nordic-Baltic Bifurcation Study III. *Circulation* 2011, 123:79-86.
11. Francesco Burzotta, . Prospective Randomized Comparison of Sirolimus- or Everolimus-Eluting Stent to Treat Bifurcated Lesions by Provisional Approach. . *J Am Coll Cardiol Intv* 2011;4:327–35.




# Coronary Bifurcation < 25% with IVUS



**IVUS 6 studies**



Left Main and Bifurcation Summit, New York 4-5/2009

# A short History of Bifurcation Treatment



Lefevre; 2014

# Single-stent Vs. Two-stent (2013) Meta-analysis (6.961 pts)




**IVUS 3 studies**

Zimarino M et al. J Am Coll Cardiol Intv 2013;6:687–95

# Long-Term Clinical Outcomes (1- vs. 2-Stent) (Mean Follow-up of 4.4 Years)

2014



Oral presentation Bo Xu, EURO PCR 2014

# Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large Side Branch.

**2015**

## The Nordic-Baltic Bifurcation Study IV

### Inclusion criteria

- Age  $\geq 18$
- Stable angina, unstable angina pectoris, NSTEMI
- Main vessel (MV)  $\geq 3.0\text{mm}$
- Side branch (SB)  $\geq 2.75\text{mm}$
- Bifurcation stenosis involving both MV and SB\*

\* ( $\geq 50\%$  diameter stenosis by visual estimation)

### Exclusion criteria


- STEMI
- Cardiogenic shock
- Other critical illness
- Relevant allergies
- Creatinine  $\geq 200$  mmol/L

EURO PCR 2015; By: I. Kumsars



# Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large Side Branch. **2015**

## The Nordic-Baltic Bifurcation Study IV




EURO PCR 2015; By: I. Kumsars



# Dispositivos Dedicados

# Classification of Dedicated Bifurcation Devices

## 1. MB stenting with provisional SB stenting



Twin-Rail



NILE




Petal



Abbott's SB  
Access DES



Antares®



BIOSS



Stentys

## 2. Side branch stents



Capella Sideguard

Tryton

## 3. Proximal



AXCESS

## 4. Bifurcated stent



Medtronic Y stent

# Summary of the Main Characteristics and Trial Results of Currently Available Dedicated Bifurcation Stents

Stent Type (Company) (Ref. #)	Device Profile	Stent Material	Drug Coating	SB Protection	Ostial SB Coverage	Study Name*	No. of Patients (Follow-Up, Months)	Additional Stenting, % MB/SB	MACCE %	Death %	MI, %	TLR, %
<b>Balloon-expandable stents</b>												
Antares† (TriReme Medical) (148)	6-F	SS	—	+	+	FIM (TOP study)	39 (1)	NA	5.9	0.0	5.1	2.9
Invatec Twin-Rail (Invatec) (149)	6-F	SS	—	+	+/-	FIM (DESIRE)	15 (7)	17/23	14.3	0.0	0.0	14.3
Multi-Link Frontier† (Abbott Vascular) (150)	7-F	SS	—	+	+/-	Registry	105 (6)	40/43	17.1	0.0	3.8	13.3
Nile Croco† (Minvasys) (151)	6-F	CoCr	—	+	+/-	Registry	93 (6)	NA	12.0	2.0	0.0	9.4
Nile Pax† (Minvasys) (152)	6-F	CoCr	Abluminal Paclitaxel	+	+/-	FIM	102 (30)	—/27	1.0	1.0	1.0	0.0
Petal (Boston Scientific) (153,154)	7-F	PtCr	Paclitaxel	+	+	FIM (Petal Trial)	28 (12)	28/25	14.8	0.0	3.7	7.4
SideKick (Y-Med) (155)	5-F	CoCr	—	+	+/-	FIM	17 (2-3)	40‡	5.8	0.0	5.8	0.0
SLK-View† (Advanced Stent Tech) (156)	8-F	SS	—	+	-	Registry	81 (4)	14/25	31.0	1.3	2.5	21.3
Tryton† (Tryton Medical) (157)	6-F	CoCr	—	NA	++	FIM (Tryton I)	30 (6)	39/—	9.9	3.3	6.6	6.6
<b>Self-expanding stents</b>												
Axxess (Devax) (32,55)	7-F	Nitinol	Abluminal Biolimus A9	+	-	Registry (DIVERGE)	302 (9)	64.7‡	7.7	0.7	4.3	4.3
Sideguard† (Cappella) (158,159)	6-F	Nitinol	—	NA	++	FIM (Sideguard I & II)	93 (12)	NA	12.0	1.2	3.6	7.2
Stentys† (Stentys) (160,161)	7-F	Nitinol	Paclitaxel	-	+/-	FIM (OPEN I)	40 (3‡, 6#)	9/13	5.1	0.0	2.5	2.5

J Am Coll Cardiol. 2010 Aug 31;56(10 Suppl):S43-78



# Dedicated bifurcation stent study in Left Main intervention

	<b>AXXESS PLUS<sup>1</sup></b> <b>N = 31</b>	<b>BiOSS Expert<sup>2</sup></b> <b>N= 54</b>	<b>Tryton<sup>3</sup></b> <b>N=52</b>
Device description	BES, self expanding nitinol stent	PES, Balloon expandable 316L stainless steel	BMS, Balloon expandable Cobalt-Chromium
Patient setting	Stable CAD	NSTE-ACS or stable	All comers
Endpoint	Safety and efficacy endpoint	Cumulative rate of death, MI, TLR	Acute gain in 3 segment Major adverse cardiac events
<b>Follow-up</b>	<b>12 month</b>	<b>12 month</b>	<b>6 month</b>
SYNTAX score	NA	21.5±6.5	20±8
Medina class 1,1,1 (%)	41%	39%	63%
Main vessel diameter (mm)	3.91±0.34	4.15±0.32	3.4±0.4
MV diameter stenosis (%)	61.2±20.2	56±26	51±17
Final kissing, (%)	NA	66.7%	94%
Adverse events, (%)	MACE 19.4 % ISA 23.8% postprocedure but no late acquired ISA	Cumulative rate 9.3%	MACE 22%
<b>Stent thrombosis, (%)</b>	<b>0</b>	<b>0</b>	<b>0</b>
TLR/TVR, (%)	TLR 9.1%	TLR 9.3%	TVR 12%
Myocardial infarction, (%)	9.7%	0	10%
<b>Death, (%)</b>	<b>0</b>	<b>0</b>	<b>0</b>

1. Hosegawa T, et al. Catheter Cardiovasc Interv 2009;73:34-41


2. Bilj, et al. J Intervcardiol 2014;27:242-51

3. Magro M, et al. Eurointervention 2013;8:1259-69

# A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions

**2015**

**F/U at 9 mo**









































Généreux, P. et al. J Am Coll Cardiol. 2015; 65(6):533-43

# Métodos Adjuntos



# Published classification of coronary bifurcation lesions.

Sanborn							
	Type I	Type II	Type III	Type IV	Type V		
Lefevre							
	Type 1	Type 2	Type 3	Type 4	Type 4a	Type 4b	
Safian							
	Type IA	Type IB	Type IIA	Type IIB	Type IIIA	Type IIIB	Type IV
Duke							
	Type A	Type B	Type C	Type D	Type E	Type F	
Medina							
	Type 1,1	Type 1,1,0	Type 1,0,1	Type 0,1,1	Type 1,0,0	Type 0,1,0	Type 0,0,1
Movahead							
	L	S	2	1m	1s	V	T


# Estratégia baseada em Classificação de Medina

ber of bifurcation components affected. Based on the Medina classification, coronary bifurcation lesions that do not involve the SB origin include type {1,0,0}, {1,1,0} and {0,1,0} lesions.

Approach-  
ing these lesions with provisional stenting has shown to be effective

Rev Esp Cardiol. 2006;59:183  
Circulation. 2009;119:71-8


# First Point: All Bifurcations are Equal ??? Not !.....



Images: Hospital Costantini

# 56 Bifurcation Treated Lesions Were Assessed By IVUS pre Intervention in Both Branches

## MEDINA Classification (Angiography Vs. IVUS Evaluation)




Costantini et.al Solaci 2011



## Caso 1


• R.G.C, 78 anos feminino, angina instável, dispnéia aos mínimos esforços, cintilo positiva com isquemia antero septal;

- HAS
- Diabetes
- Dislipidemia
- Obesidade
- LVEF= 75 %






# Angiografia Medina (0,1,0)

## IVUS Medina (1,1,1)






# IVUS, Stent Boost & OCT



Images: Hospital Costantini

# Apresentação clínica

- M.C.J, 71 anos masculino, ATC prévia 2005 (CX) e 2011 (TC>DA e CX),
- 2014 (Reestenose / CX ÓSTIO ?)
- 2015 novos sintomas (Angina estável) – novo cat
- Nova reestenose (DA/CX) ----- Indicação cirúrgica
- Cintilo Normal e teste com taquicardia supraventricular sustentada com aberrância de condução à partir do 7º minuto do esforço.





- HAS
- Dislipidemia
- Stress
- Diabetes

# 2011




## Oque vc Faria ?



# Angioplastia TCESQ Envolvendo Bifurcação DA/CX Guiada por angiografia (Outro serviço em 2011)




# Nova Angioplastia 2014 Outro serviço






# 2015

## Indicação Cirurgica





# 2015


## Indicação Cirurgica ????



# ATC CX Distal



# Impact of IVUS in bifurcation lesions, (COBIS) – 2011 – IVUS 2 vessels



IVUS guidance during DES implantation at bifurcation lesions may be helpful to improve long-term clinical outcomes by reducing the occurrence of death or MI.

AHJ 2011, 161, 180~187



# Meta-Analysis of Long Term Outcomes of IVUS Vs. Angiographic-Guided PCI of Bifurcation Lesions

Death + Stent Thrombosis + Myocardial Infarction

**Year - 2013**



Study

ID

**Four observational studies with 7,123 patients were included for analysis.**

OR (95% CI)

Biondi-Zoccai G (2011)



2.02 (1.29, 3.19)

Kim JS (2011)



0.04 (0.02, 0.06)

Chen SL (2013)



0.07 (0.05, 0.11)

Patel Y (2012)



0.06 (0.04, 0.10)

Overall (I-squared = 98.3%, p = 0.000)



0.14 (0.02, 0.82)

NOTE: Weights are from random effects analysis

.0226

IVUS-Guided Better

1

Angio-Guided Better

1.2

Patel VG; Circulation. 2013; 128: A14804



# Meta-Analysis of Long Term Outcomes of IVUS Vs. Angiographic-Guided PCI of Bifurcation Lesions

## Component Outcomes Composite of Death, Stent Thrombosis, MI


	<b>IVUS n = 1757</b>	<b>Angio n = 5366</b>	<b>Odds Ratio</b>	<b>p Value</b>
<b>Death</b>	<b>3.4</b>	<b>12.0</b>	<b>0.137</b>	<b>&lt;0.001</b>
<b>Stent thrombosis</b>	<b>0.7</b>	<b>5.2</b>	<b>0.519</b>	<b>0.034</b>
<b>MI</b>	<b>2.7</b>	<b>4.3</b>	<b>0.434</b>	<b>0.051</b>
<b>TLR</b>	<b>8.6</b>	<b>12.3</b>	<b>0.649</b>	<b>0.212</b>

Patel VG; Circulation. 2013; 128: A14804





# Clinical Presentation

- A.P.V, 66 years old female, unstable angina positive tallium test mid-basal lateral & antero-lateral wall.






- Hypertension
- Hyperlipidemia
- Diabetes
- Sedentary
- LVEF= 72%






# IVUS Approach











**Wrong Way**






# Final Result



# Follow Up @ 5 Yrs

## Positive Thallium test lateral wall



**CLINICAL RESPONSIBILITY !!!**

# Tronco de Coronária Esquerda

**Left Main**






**MACCE**



**TROMBOSIS**







**Vorpahl M, Virmani R. presented ACC 2010**

# Who Was Thrombogenic: The Stent or the Doctor?

Patrick W. Serruys, MD, PhD; Carlo Di Mario, MD, PhD

**1995**

Patrick Serruys. *Circulation*. 1995;91:1891-1893

# 2014 ESC/EACTS Guidelines on Myocardial Revascularization

## Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD with suitable coronary anatomy for both procedures and low predicted surgical mortality


Recommendations according to extent of CAD	CABG		PCI	
	Class <sup>a</sup>	Level <sup>b</sup>	Class <sup>a</sup>	Level <sup>b</sup>
One or two-vessel disease without proximal LAD stenosis.	IIb	C	I	C
One-vessel disease with proximal LAD stenosis.	I	A	I	A
Two-vessel disease with proximal LAD stenosis. ?	I	B	I	C
Left main disease with a SYNTAX score ≤ 22. ?	I	B	I	B
Left main disease with a SYNTAX score 23–32.	I	B	IIa	B
Left main disease with a SYNTAX score >32.	I	B	III	B
Three-vessel disease with a SYNTAX score ≤ 22.	I	A	I	B
Three-vessel disease with a SYNTAX score 23–32.	I	A	III	B
Three-vessel disease with a SYNTAX score >32.	I	A	III	B

Windecker et al., Eur Heart J. 2014 Aug 29. pii: ehu278


?????????

# Left Main Technique


## PROVIONAL




## TAP



## CRUSHING



## CULOTTE




Source: Hospital Costantini registry PCI in UPLM.



# First Point: All Left Main are Equal ???


## Not !.....

**Euro Score 4**  
**Inter. Risk**




**Syntax Score 18**  
**Low Risk**

**Euro Score 2**  
**Low Risk**



**Syntax Score 23**  
**Inter. Risk**

**Euro Score > 6**  
**High Risk**




**Syntax Score 36**  
**High Risk**

Source: Hospital Costantini registry PCI in UPLM.


# Second Point: Follow Up

**Follow Up 8 mo**



**Syntax Score 18**  
**Low Risk**

**Follow Up 16 mo**



**Syntax Score 23**  
**Inter. Risk**

**Follow Up 5 yo**




**Syntax Score 36**  
**High Risk**

Source: Hospital Costantini registry PCI in UPLM.


# Clinical Presentation

- W.S, 61 years old male, with stable angina Class II, positive treadmill test,
- **Syntax Score 36 – Euro Score > 6**









- Family history
- Hyperlipidemia
- Former smoker
- LVEF= 51%

# Angiography + IVUS pre procedure









# Left Main PCI

Image pre & last 5 yrs - stents 1<sup>a</sup> generation.



2009 pre PCI



2014 FU @ 5 YRS




# Follow Up @ 5 Yrs (Taxus & Cypher)



# MACCE to 5 Years Left Main Subsets



**< 10% with IVUS ???**



■ CABG (n=348)    ■ TAXUS (n=357)


Mohr FW et al. Lancet 2013;381:629-38



# Syntax


## MACCE to 5 years

### LM Distal PCI Bifurcations: 1 vs $\geq 2$ stents



TCT 2014; Oral presentation Marie-Claude MORICE

# Minimal stent area threshold values for the prediction of angiographic in-stent restenosis




- ✓ MACE-free survival was lower in pts with underexpansion vs those without underexpansion (89.4% vs 98.1%)
- ✓ TLR-free survival was lower in pts with underexpansion vs no underexpansion (90.9% vs 98.5%).
- ✓ Although acute malapposition was observed in 28 pts, malapposition was not related to MACE at follow-up.

Kang S et al. Circ Cardiovasc Interv. 2011;4:562-569

# Comprehensive Intravascular Ultrasound Assessment of Stent Area and Its Impact on Restenosis and Adverse Cardiac Events in 403 Patients With Unprotected Left Main Disease

## Under Expansion Mortality Predictor !!!!




### Conclusion

A smaller IVUS-MSA within any one of these segments was responsible for a higher rate of angiographic ISR and clinical MACE. Correcting underexpansion with these optimal IVUS criteria using IVUS guidance during LM stenting procedures may reduce cardiac events after DES treatment for unprotected LM disease.

Kang S et al. Circ Cardiovasc Interv. 2011;4:562-569






- V.S.N, 79 years old male, Atrial fibrillation, ACS NSST;
- **Syntax Score 28 – Euro Score > 6**

- **Family history**
- **Diabetes**
- **Hyperlipidemia**
- **Former smoker**
- **LVEF= 51%**






# Final Result



# Summary





3:15 hs of procedure  
65 min X Ray  
350 ml de Contrast

- ✓ IVUS
- ✓ Stent BOOST
- ✓ Kissing Balloon
- ✓ Patience

# MACCE to 5 Years Left Main Subsets



**< 10% with IVUS ???**



**CABG (n=348)**      **TAXUS (n=357)**

Mohr FW et al. Lancet 2013;381:629-38

# The First Brazilian Registry UPLM PCI

Revista Brasileira de Cardiologia Invasiva  
© 2011 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista

Vol. 19, Nº 2, 2011  
ISSN 0104-1843

---

Artigo Original

## Evolução Clínica de Pacientes com Lesões de Tronco de Coronária Esquerda Não-Protegido Submetidos a Angioplastia Coronária com Implante de Stents Farmacológicos

Costantino R. Costantini<sup>1</sup>, Daniel Zanuttini<sup>1</sup>, Marcos A. Denk<sup>1</sup>, Sergio G. Tarbine<sup>1</sup>, Marcelo F. Santos<sup>1</sup>, Eduardo F. Oliveira<sup>1</sup>, Marcos H. Bubna<sup>1</sup>, José F. Rocha<sup>1</sup>, Marcos J. Barbosa<sup>1</sup>, Costantino O. Costantini<sup>1</sup>

Costantini et al. RBCI; Junho, 2011;19(2): 153-9




# In Hospital Outcomes

(n= 255 pts)

Procedural Success 99,8%

Discharge: 99,18%

**Hospital Costantini  
Left main Registry**




Hospital Costantini Registry LM PCI

# Follow Up mean 6,5 yrs (n= 255 pts)

BIFURCATION = 87,3%  
MULTIVESSEL = 79%  
SYNTAX SCORE  $\geq$  33 = 44%  
EUROSCORE > 6 = 49%  
**96,6 % IVUS**

CABG Results (F/U mortality)  
**Cleveland: 11,3 (1 year)**  
**NYS Database: 9,6 (2 years)**  
**Duke Database: 10,29 (2 years)**

## Hospital Costantini Left main Registry




Hospital Costantini Registry LM PCI

# Bioresorbable scaffolds

## Bioresorbable scaffolds on the bench

John Ormiston<sup>1,2,6\*</sup>, MBChB; Pascal Motreff<sup>3</sup>, MD; Olivier Darremont<sup>4</sup>, MD; Bruce Webber<sup>2</sup>, MHSc; Patrice Guerin<sup>5</sup>, MD; Mark Webster<sup>2,6</sup>, MBChB




The interventionalist needs to understand the different BRS performance characteristics in order to select appropriate coronary lesions for BRS, and to deliver, deploy and post-dilate BRS appropriately and safely. Because polymeric BRS struts may break more readily than those of metallic stents it is essential that the interventionalist understands safe balloon size and pressure post-dilatation limits. It is likely that the “T” strategy with a metallic drug-eluting stent is the best strategy if, after deployment of an MB scaffold, the SB needs treatment. The culotte, crush and SKS strategies have important disadvantages, including technical difficulty, multiple strut layers and the potential for strut fracture. The withdrawal of a trapped wire during a provisional SB strategy causes a limited amount of polymer coating damage.



289 patients, 302 bifurcation lesions from 10 centers (86% provisional)

## Kaplan-Meier Estimates of Definite Stent Thrombosis



Diabetes mellitus	25%
ACS at presentation	34%
Prasugrel or ticagrelor	19%
True bifurcation	45%
Predilation of MB	95%
Postdilation of MB	61%
FKBI	19%
IVUS	22%
OCT	21%

289 patients with 302 bifurcation lesions from 10 centers (86% provisional)


Case	DM	ACS	Medina	Technique	Post-dilation on MB	KBI	OCT and/or IVUS	P2Y12 inhibitor	On DAPT
1	Yes	No	1,1,1	Single	Yes	No	Yes	Clopidogrel	No
2	No	No	0,1,0	Single	No	No	No	Clopidogrel	Yes
3	No	Yes	1,0,0	Single	No	No	Yes	Clopidogrel	Yes
4	No	Yes	1,1,1	Single	No	No	No	Ticlopidine	Yes
5	Yes	Yes	1,1,0	Single	No	No	No	Clopidogrel	Yes
6	No	Yes	1,1,1	Double*	Yes	No	No	Clopidogrel	No
7	No	Yes	1,1,0	Single	No	No	No	Clopidogrel	Yes
8	Yes	Yes	1,1,0	Single	No	No	No	Clopidogrel	Yes
9	Yes	Yes	0,0,1	Single	No	Yes	No	Prasugrel	Yes

\*DES on SB. Favorable characteristics are shown in green. Unfavorable characteristics are shown in red.



# Early Scaffold Thrombosis And Bifurcation Rate

Meta-regression of 3,386 patients undergoing BVS-PCI from 8 Registries



10th European Bifurcation Club; 2014, Capodanno D. Tamburino C. Unpublished

# Apresentação clínica

- J.M, 69 masculino, Ergometria com TVNS prévia.
- Angiotomo com piora da lesão em DA/Dg desde a última análise.....(2011)
- Cintilografia: 2011; 2013 e 2015 (com perfusão homogênea)



2015



- Hipertensão
- Dislipidemia
- Stress



# Angiotomo



# Arritmias

## CINTILOGRAFIA DE PERFUSÃO MIOCÁRDICA

### 2011

Imagens tomográficas do coração foram obtidas após a administração venosa de sestamibi-<sup>99m</sup>Tc em repouso e após exercício isotônico. A aquisição das imagens foi sincronizada ao eletrocardiograma para análise da função ventricular esquerda (GSPECT).

O Teste de Esforço Cardiopulmonar teve duração de 10:31 minutos, protocolo de Rampa, atingindo 80% da FC máxima prevista e um volume pico de oxigênio de 29,4ml/kg/min (aproximadamente 8 METs). O paciente manteve-se assintomático, sem alterações significativas do segmento ST. Apresentou 01 episódio de taquicardia supraventricular não sustentada (menos de 10 segundos), 2 extrassístoles ventriculares pareadas e 01 episódio de taquicardia ventricular não sustentada de 7 batimentos no pico do esforço. Na recuperação apresentou extrassístoles supraventriculares isoladas frequentes.

## CINTILOGRAFIA DE PERFUSÃO MIOCÁRDICA


### 2013

Imagens tomográficas do coração foram obtidas após a administração venosa de sestamibi-<sup>99m</sup>Tc em repouso e após exercício isotônico. A aquisição das imagens foi sincronizada ao eletrocardiograma para análise da função ventricular esquerda (GSPECT).


O Teste de Esforço Cardiopulmonar teve duração de 9:51 minutos, protocolo de Rampa, atingindo 89% da FC máxima prevista e um consumo pico de oxigênio (VO<sup>2</sup> pico) de 29,4 ml/kg/min. (aproximadamente 8 METs). Não revelou alterações clínicas ou eletrocardiográficas sugestivas de resposta isquêmica do miocárdio. Apresentou extrassístoles supraventriculares e ventriculares frequentes, vários episódios pareados e múltiplos episódios de taquicardia ventricular não sustentada de até 5 batimentos no esforço e no início da recuperação. Regular capacidade aeróbica.



# ECG (Fev 2015)




08:36 (128 Bpm)






08:39 (128 Bpm)

# Angiografia / IVUS

2009





2015








# Angiografia / (FFR adenosina e.v - 140µg/kg/min)

## 2015




# Angiografia + IVUS (2015)





**Basal**



**3.0\*10  
16 Atms**

**CB**




**Pós Balão**



**3.5\*10  
10 Atms**

**CB**






**Pós Cutting**



# Angiografia / FFR / OCT


## Resultado Final





# Teste Ergométrico com 35 dias


## Protocolo de Bruce 11 Mets (10:10 min)



# Bioreabsorbable Vascular Scaffold C Costantini Initial Experience (n= 34 pts – 62 Lesões - 74 stents)

## In Hospital Outcomes

**C Costantini  
BVS Registry**



Source: C Costantini Experience



# Follow Up mean 5,9 mo

(n= 34 pts – 62 Lesões - 74 stents)

MULTIVESSEL = 63%

EUROSCORE > 6 = 42%


Bifurcation = 25 %

100 % post dilatation

100 % IVUS / 96% OCT

**Lesões B/C:76%**  
**BIFURCATIONS**  
**25%**

**C Costantini**  
**BVS Registry**



Source: C Costantini Experience

# Barreras para el diagnóstico y tratamiento adecuado : Un problema multifactorial

## SISTEMA de SALUD (1)

### POLÍTICO

- Educación para la Salud , Enfoque sobre la enfermedad en lugar de la prevención;
- Recursos limitados/Costos e La falta de información oportuna y adecuada.
- Entre 20 a 40 % del dinero invertido en salud se desperdicia en BRASIL .... revela un informe de la OMS (2013 )

## PACIENTE (2)

### IGNORANCIA

- La falta de conocimiento o motivación;
- No visite al médico;
- Bajo cumplimiento al tratamiento;
- Los factores culturales y sociales???

## MEDICO (2)

### MAESTRO DIOS

- Subestima el riesgo real del paciente , centrándose en los factores de riesgo individual en lugar de abordar el riesgo Cardiovascular...
- Error al buscar en los objetivos;
- Seguimiento y asesoramiento inapropiado paciente;
- La capacitación inadecuada sobre la forma de aplicar el consejo médico.

1. Pearson TA, et al. *J Am Coll Cardiol.* 1996;27:1039-1047.
2. Hobbs FD, et al. *Fam Pract.* 2002;19:596-604.



# Bifurcation is....Time

**T** echnique  
**I** mage  
**M** aterial  
**E** xperience

**Time = Patience**

Costantino Costantini

# Tratamiento de la Insuficiência Coronária

“Si pensamos siempre en el PACIENTE, estamos  
trabajando correctamente.

Si no es asi , NO ES ETICO”.



Professor Adib Jatene (J. Globo 27-9-13)





# Cardio Interv

# 2015



**15 th International Interventional Cardiology Symposium**  
**November 26, 27 - Curitiba - Brazil**



**Conferences, discussions, round tables and live cases.**





# Cardio Interv

# 2015



**15 th International Interventional Cardiology Symposium**  
**November 26, 27 - Curitiba - Brazil**



**Conferences, discussions, round tables and live cases.**